Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat
2014 (English)In: Leukemia research: a Forum for Studies on Leukemia and Normal Hemopoiesis, ISSN 0145-2126, E-ISSN 1873-5835, Vol. 38, no 7, 816-821 p.Article in journal (Refereed) Published
YKL-40 regulates vascular endothelial growth factors and induces tumor proliferation. We investigated YKL-40 before and after treatment with vorinostat in 31 polycythemia vera (PV) and 16 essential thrombocythemia (ET) patients. Baseline PV patient levels were 2 times higher than in healthy controls (P<0.0001) and 1.7 times higher than in ET (P = 0.02). A significant correlation between YKL-40 at baseline and neutrophils, CRP, LDH, JAK2V617F and platelets in PV patients was observed, as well as a significantly greater reduction of YKL-40 levels in PV patients responding to therapy. YKL-40 might be a novel marker of disease burden and progression in myeloproliferative neoplasms. (C) 2014 Elsevier Ltd. All rights reserved.
Place, publisher, year, edition, pages
2014. Vol. 38, no 7, 816-821 p.
Yk1-40, Essential thrombocythemia, Polycythemia vera, Vorinostat, Phase II study
Hematology Cancer and Oncology
IdentifiersURN: urn:nbn:se:uu:diva-230512DOI: 10.1016/j.leukres.2014.04.002ISI: 000339339400015OAI: oai:DiVA.org:uu-230512DiVA: diva2:744418